Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (SHE:301096)
China · Delayed Price · Currency is CNY 49.30
+2.21 (4.69%)
Sep 30, 2026, 4:00 PM EDT
SHE:301096 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
| 5,347 | 6,197 | 4,115 | 7,091 | 7,389 | 9,293 | |
Market Cap Growth | -17.90% | 50.61% | -41.97% | -4.04% | -20.49% | - |
Enterprise Value | 5,927 | 6,691 | 4,256 | 6,460 | 6,057 | 9,416 |
Last Close Price | 49.30 | 57.14 | 37.94 | 64.78 | 67.17 | 83.80 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 26.07 | 38.06 | 83.65 |
Forward PE | - | 116.61 | 12.33 | 21.10 | 26.68 | - |
PS Ratio | 8.22 | 9.14 | 5.13 | 6.97 | 12.17 | 24.83 |
PB Ratio | 2.14 | 2.49 | 1.60 | 2.64 | 2.98 | 4.01 |
P/TBV Ratio | 2.22 | 2.58 | 1.66 | 2.74 | 3.08 | 4.12 |
P/OCF Ratio | - | - | - | 78.39 | 28.48 | 63.90 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 9.12 | 9.87 | 5.31 | 6.35 | 9.97 | 25.15 |
EV/EBITDA Ratio | 106.77 | 89.98 | 42.74 | 18.51 | 33.90 | 67.75 |
EV/EBIT Ratio | - | - | - | 24.75 | 49.50 | 84.55 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.39 | 0.35 | 0.28 | 0.14 | 0.00 | 0.12 |
Debt / EBITDA Ratio | 17.55 | 11.63 | 7.12 | 1.05 | 0.05 | 1.93 |
Net Debt / Equity Ratio | 0.23 | 0.20 | 0.08 | -0.19 | -0.49 | -0.75 |
Net Debt / EBITDA Ratio | 10.58 | 6.73 | 2.01 | -1.46 | -6.88 | -12.45 |
Net Debt / FCF Ratio | -3.94 | -1.98 | -0.34 | 0.86 | 3.70 | 16.80 |
Asset Turnover | 0.17 | 0.18 | 0.22 | 0.31 | 0.21 | 0.21 |
Inventory Turnover | 2.06 | 2.36 | 2.88 | 4.42 | 4.46 | 9.26 |
Quick Ratio | 1.52 | 1.40 | 1.64 | 1.68 | 5.15 | 4.53 |
Current Ratio | 1.85 | 1.69 | 2.01 | 1.90 | 5.54 | 4.71 |
Return on Equity (ROE) | -3.62% | -3.57% | -2.01% | 10.53% | 8.09% | 8.35% |
Return on Assets (ROA) | -1.71% | -1.39% | -0.77% | 4.95% | 2.61% | 3.91% |
Return on Invested Capital (ROIC) | -3.41% | -2.86% | -1.85% | 14.02% | 13.30% | 21.91% |
Return on Capital Employed (ROCE) | -3.70% | -3.00% | -1.50% | 9.20% | 4.60% | 4.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Earnings Yield | -1.72% | -1.46% | -1.28% | 3.84% | 2.63% | 1.20% |
FCF Yield | -2.75% | -4.08% | -14.36% | -8.44% | -4.50% | -1.11% |
Dividend Yield | - | - | - | 0.46% | 1.19% | 0.72% |
Payout Ratio | - | - | - | 34.12% | 34.28% | 9.11% |
Buyback Yield / Dilution | -30.43% | -1.18% | 0.66% | 0.11% | -33.77% | -0.29% |
Total Shareholder Return | -30.43% | -1.18% | 0.66% | 0.57% | -32.58% | 0.42% |